Join the Exenatide group to help and get support from people like you.
Exenatide News
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...
Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021--AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 d...
FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
April 3, 2018 AstraZeneca today announced the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin...
FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes
23 October 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of By...
FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes
Monday March 3, 2014 – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an...
FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...
Ask a question
To post your own question to this support group, sign in or create an account.